Patient P-02236

Synthetic patientMETA-24 · Day 125 · 35–44 · M · baseline S14Steering view · 3D Open companion preview

Therapy response

Declining

Tolerance

Deteriorating

GI state

Unstable

Inflammatory state

Stable

Nutritional resilience

Unstable

Discontinuation risk

73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 71 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 72 GI-04 recommended — GI Support Protocol GI-04
Day 73 Patient accepted — Started GI-04 in the companion
Day 81 GI symptom burden −27% vs expected — GI Support Protocol GI-04
Day 86 ME-01 recommended — Monitoring Escalation ME-01
Day 87 Tolerance state changed — Unstable → Improving
Day 87 Patient accepted — Started ME-01 in the companion
Day 90 Deterioration detected before clinical escalation — Monitoring Escalation ME-01

What changed?

Trajectory began diverging from predicted response on Day 71.

Primary contributors, last 14 days

Treatment adherence-13
Toxicity+5

What helped?

GI Support Protocol GI-04Day 72
Result: symptom burden −27%
Monitoring Escalation ME-01Day 86
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

63%

probability of meaningful tolerance improvement

284 similar trajectories
69% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

37 min

stable · -1.4 vs previous 14 d

Sleep duration

Wearable

7.1 h

stable · +0.0 vs previous 14 d

Energy level

Daily log

3.6/10

stable · -0.1 vs previous 14 d

Steps

Wearable

4,398

stable · -55 vs previous 14 d

GI burden

Companion

61.5/100

stable · +1.4 vs previous 14 d

Adherence

Companion

51.2 %

worsening · -12.4 vs previous 14 d

Sleep quality

Wearable

29.7/100

stable · -1.3 vs previous 14 d

Glucose, CGM daily mean

CGM

150 mg/dL

stable · +2.4 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards failing · 26 from the failing basin, 64 from restoration.

Would help

NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 74%
SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 74%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 74%
More protein
GI -10.2 next day on high-intake days · n 23

Would not help

Keep histamine low
GI +9.1 next day on high-intake days · n 25
Keep fat low
GI +9 next day on high-intake days · n 24
Keep ultra-processed low
GI +8.6 next day on high-intake days · n 29

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Protein
-10.2supporter · 95%
Histamine load
+9.1detractor · 95%
Dietary fat load
+9detractor · 95%
Ultra-processed food
+8.6detractor · 95%
Simple carbohydrates
+6.3detractor · 95%
Insoluble fibre
+3.8detractor · 58%
Alcohol
+2.1no signal · 23%
Caffeine
-0.6no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Inflammatory signalling ↓85
- DNAIL6 -174 variant raises baseline inflammatory tone
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 55
- WearableHRV 24 ms, trending down
Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 62 and rising
Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 42/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓25
- WearableResting HR 74 bpm
Drug metabolism and exposure ↑20
- BloodToxicity index 48

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
IL6 -174 G/C
Higher inflammatory tone
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 2.6 · butyrate capacity 42/100

Akkermansia muciniphilaLow
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 25 ms
Sleep: 6.8 h
Steps: 4,355
Resting HR: 75 bpm

Daily log: GI score 62, nutritional resilience 40, adherence 51.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02142	52%	S14	GI-04	improved	42
P-02149	48%	S14	GI-04	improved	50
P-02118	46%	S14	GI-04	improved	47
P-02244	46%	S14	GI-04	improved	46
P-02508	45%	S14	ME-01	improved	51
P-02125	44%	S14	GI-04	improved	55
P-02132	44%	S14	SC-12	improved	40
P-02159	44%	S14	GI-04	improved	47
P-02268	43%	S14	GI-04	improved	43
P-02381	43%	S14	SC-12	improved	52
P-02648	43%	S14	SC-12	improved	47
P-02018	42%	S01	GI-04	improved	46